113 related articles for article (PubMed ID: 17041001)
1. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
[TBL] [Abstract][Full Text] [Related]
2. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Fujii N; Hamano T; Mikami S; Nagasawa Y; Isaka Y; Moriyama T; Horio M; Imai E; Hori M; Ito T
Nephrol Dial Transplant; 2007 Jun; 22(6):1601-7. PubMed ID: 17124283
[TBL] [Abstract][Full Text] [Related]
3. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
[TBL] [Abstract][Full Text] [Related]
4. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
[TBL] [Abstract][Full Text] [Related]
5. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
[TBL] [Abstract][Full Text] [Related]
6. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
7. Weekly risedronate in kidney transplant patients with osteopenia.
Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; RubĂ S; Oppenheimer F
Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
[TBL] [Abstract][Full Text] [Related]
8. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
[TBL] [Abstract][Full Text] [Related]
9. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
10. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
11. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
12. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
13. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.
Frost ML; Cook GJ; Blake GM; Marsden PK; Fogelman I
J Clin Densitom; 2007; 10(1):46-54. PubMed ID: 17289526
[TBL] [Abstract][Full Text] [Related]
14. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
15. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
Kinov P; Tivchev P; Doukova P; Leithner A
Acta Orthop Belg; 2006 Jan; 72(1):44-50. PubMed ID: 16570894
[TBL] [Abstract][Full Text] [Related]
16. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.
Mok CC; To CH; Mak A; Ma KM
Arthritis Rheum; 2005 Dec; 52(12):3997-4002. PubMed ID: 16320346
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Denk E; Hillegonds D; Hurrell RF; Vogel J; Fattinger K; Häuselmann HJ; Kraenzlin M; Walczyk T
J Bone Miner Res; 2007 Oct; 22(10):1518-25. PubMed ID: 17576167
[TBL] [Abstract][Full Text] [Related]
20. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]